ABSTRACT
RNA amplification tests allow sensitive detection of SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed “Harmony COVID-19”, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device that processes up to 4 samples simultaneously. Our lyophilized reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect as little as 15 SARS-CoV-2 RNA copies per reaction, and it can report as early as 17 min for samples with high viral load (2 x 105 RNA copies per reaction). Analysis of RNA extracted from clinical nasal specimens (n = 101) showed 95% concordance with RT-PCR, including 100% specificity in specimens positive for other viruses and bacteria. Analysis of contrived samples in the nasal matrix showed detection of 92% or 100% in samples with ≥20 or ≥100 particles per reaction, respectively. Usability testing showed 95% accuracy by healthcare workers operating the test for the first time.
ONE SENTENCE SUMMARY Harmony COVID-19: point-of-care SARS-CoV-2 RNA detection
Competing Interest Statement
E.K., N.P., Q.W., I.H., D. L., R. A., M.P.,and B.R.L. are inventors on one or more patent applications related to this work. E.K., N.P., Q.W., I.H., D. L., R. A., M.P.,A.K.O, C.B., and B.R.L. hold equity in a startup company that licenses this technology.
Funding Statement
This work was supported by the Seattle Flu Study (funded by Gates Ventures) and the National Institutes of Health (R01AI140845; 5R61AI140460-03). We thank the Washington Entrepreneurial Research Evaluation and Commercialization HUB program (WE-REACH, U01 HL152401) and their matching grant partners for partly supporting reagents, supplies, and personnel. I.T.H. was supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM008268. This work does not reflect the views of the funders. The funders were not involved in the design of the study, and funders do not have any ownership over the management and conduct of the study, the data, or the rights to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These specimens were collected with informed consent as part of the Seattle Flu Study, approved by the Institutional Review Board at the University of Washington (IRB: STUDY0006181). The Harmony usability study was approved by the Institutional Review Board at the University of Washington (IRB: STUDY00010884), and informed consent was provided by participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials availability: All data are presented in the main text and supplementary information.
